G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

24 March 2026 The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.

Europe

EPO reports record patent filings, but pharma and biotech lag

24 March 2026 The European Patent Office’s Technology Dashboard reveals only a slight increase in medtech filings, and drops in biotech and pharma, against an overall healthy backdrop.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

More features

EPO reports record patent filings, but pharma and biotech lag

HSF Kramer hires patent litigator as partner in Germany

Abbott IP chief: ‘Firms without AI policies scare me’

Emotional Perception: What next for patent holders?

Generic rival blocked as AZ defends diabetes stronghold

The curtain closes on three major drug disputes

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

G 2/21: how to support inventive steps in patentability

More on this story

Editor's picks

Editor's picks

More features